Pham Ngoc-Yen T, Cruz Diego, Madera-Marin Luis, Ravender Raja, Garcia Pablo
Division of Nephrology, University of New Mexico School of Medicine, Albuquerque, NM 87106, USA.
Hospital General San Juan de Dios, Guatemala City 01001, Guatemala.
J Clin Med. 2024 Jan 30;13(3):793. doi: 10.3390/jcm13030793.
Post-transplant diabetes mellitus (PTDM) is a common occurrence in post-kidney transplantation and is associated with greater mortality, allograft failure, and increased risk of infections. The primary goal in the management of PTDM is to achieve glycemic control to minimize the risk of complications while balancing the need for immunosuppression to maintain the health of the transplanted kidney. This review summarizes the effects of maintenance immunosuppression and therapeutic options among kidney transplant recipients. Patients with PTDM are at increased risk of diabetic kidney disease development; therefore, in this review, we focus on evidence supporting the use of novel antidiabetic agents and discuss their benefits and potential side effects in detail.
移植后糖尿病（PTDM）在肾移植后很常见，与更高的死亡率、移植肾失功及感染风险增加相关。PTDM管理的主要目标是实现血糖控制，以将并发症风险降至最低，同时平衡免疫抑制需求以维持移植肾的健康。本综述总结了肾移植受者维持性免疫抑制的效果及治疗选择。PTDM患者发生糖尿病肾病的风险增加；因此，在本综述中，我们重点关注支持使用新型抗糖尿病药物的证据，并详细讨论其益处和潜在副作用。
